Actively Recruiting
TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer
Led by The Netherlands Cancer Institute · Updated on 2026-05-13
100
Participants Needed
7
Research Sites
242 weeks
Total Duration
On this page
Sponsors
T
The Netherlands Cancer Institute
Lead Sponsor
D
Dutch Cancer Society
Collaborating Sponsor
AI-Summary
What this Trial Is About
This prospective, national, multi-centre study will include patients with stage III triple-negative breast cancer (TNBC) who are planned to start with standard (neo)adjuvant systemic treatment. The study will gather clinico-pathological, treatment and follow-up information of participating patients through Dutch databases. Participating patients will be asked to complete cancer specific and more generic quality of life questionnaires at nine time points during and after their anticancer treatment in a mobile application. For all patients who have consented to additional blood collection, to assess the course of dynamic ctDNA during (neo)adjuvant chemotherapy and its relation with outcome, two tubes will be collected at four different time points.
CONDITIONS
Official Title
TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older
- Histologically confirmed adenocarcinoma of the breast
- Assumed clinical or pathological stage III (TNM) breast cancer
- Breast tumor must be HER2-negative (score 0 or 1 at immunohistochemistry or score 2 at immunohistochemistry and negative at in situ hybridization)
- Breast tumor must be hormone receptor negative (estrogen receptor <10% and progesterone receptor <10%, or for histological grade III tumor estrogen receptor <50% and progesterone receptor <50%)
- Patients planned to receive complete standard care in the Netherlands including neo-adjuvant chemotherapy
- Patients able to use a mobile phone, tablet, laptop, or computer and understand Dutch
You will not qualify if you...
- Evidence of distant metastases based on staging examinations according to Dutch guidelines
- Patients only treated systemically in the adjuvant setting
- Participation in another clinical study with a treatment intervention during this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Medical spectrum Twente
Enschede, Overijssel, Netherlands, 7500 KA
Actively Recruiting
2
Amsterdam University Medical Center
Amsterdam, Netherlands
Not Yet Recruiting
3
The Netherlands Cancer Institute
Amsterdam, Netherlands
Actively Recruiting
4
Amphia
Breda, Netherlands
Not Yet Recruiting
5
UMCG
Groningen, Netherlands, 9713 GZ
Actively Recruiting
6
Maastricht University Medical Center
Maastricht, Netherlands
Actively Recruiting
7
ErasmusMC
Rotterdam, Netherlands
Actively Recruiting
Research Team
P
Pien Debets, Study coordinator
CONTACT
I
Ingrid Mandjes, Clinical Projects Manager
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here